US009409146B2

(12) **United States Patent**
Frangione et al.

(10) **Patent No.: US 9,409,146 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **METHOD FOR TREATING AMYLOID DISEASE**

(71) Applicant: **New York University**, New York, NY (US)

(72) Inventors: **Blas Frangione**, New York, NY (US); **Einar M. Sigurdsson**, Scarsdale, NY (US); **Thomas Wisniewski**, Staten Island, NY (US); **Jorge Ghiso**, Elmhurst, NY (US)

(73) Assignee: **New York University**, New York, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/655,234**

(22) Filed: **Oct. 18, 2012**

(65) **Prior Publication Data**

US 2013/0045216 A1 Feb. 21, 2013

Related U.S. Application Data

(62) Division of application No. 12/366,126, filed on Feb. 5, 2009, now Pat. No. 8,318,175, which is a division of application No. 10/540,294, filed as application No. PCT/US03/40744 on Dec. 18, 2003, now abandoned.

(60) Provisional application No. 60/434,736, filed on Dec. 19, 2002.

(51) **Int. Cl.**

A61K 38/17	(2006.01)
B01D 61/00	(2006.01)
A61K 39/395	(2006.01)
A61P 25/28	(2006.01)
B01J 20/28	(2006.01)
A61K 31/739	(2006.01)
A61K 38/30	(2006.01)
A61K 38/38	(2006.01)
A61K 38/39	(2006.01)
A61K 38/55	(2006.01)
B01J 20/32	(2006.01)
B01J 20/34	(2006.01)
A61M 1/34	(2006.01)

(52) **U.S. Cl.**

CPC ***B01J 20/28033*** (2013.01); ***A61K 31/739*** (2013.01); ***A61K 38/1709*** (2013.01); ***A61K 38/30*** (2013.01); ***A61K 38/38*** (2013.01); ***A61K 38/39*** (2013.01); ***A61K 38/55*** (2013.01); ***B01J 20/3206*** (2013.01); ***B01J 20/3208*** (2013.01); ***B01J 20/3217*** (2013.01); ***B01J 20/3219*** (2013.01); ***B01J 20/3246*** (2013.01); ***B01J 20/3248*** (2013.01); ***B01J 20/3274*** (2013.01); ***B01J 20/345*** (2013.01); ***B01J 20/3475*** (2013.01); *A61M 1/34* (2013.01); *B01J 2220/58* (2013.01); *B01J 2220/66* (2013.01)

(58) **Field of Classification Search**

USPC 210/645; 514/1.1, 17.8; 424/172.1

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,409,105	A	10/1983	Hayashi et al.
4,770,774	A	9/1988	Ida et al.
5,216,127	A	6/1993	Hirai et al.
5,434,170	A	7/1995	Andrulis, Jr.
5,604,102	A	2/1997	McConlogue et al.
5,679,775	A	10/1997	Boos et al.
5,817,528	A	10/1998	Bohm et al.
5,948,763	A	9/1999	Soto-Jara et al.
6,274,615	B1	8/2001	Pappolla et al.
6,713,450	B2	3/2004	Frangione et al.
7,195,761	B2	3/2007	Holtzman et al.
7,427,655	B2	9/2008	Frangione et al.
7,479,482	B2	1/2009	Frangione et al.
7,700,107	B2	4/2010	Frangione et al.
7,732,568	B2	6/2010	Mattner
7,892,545	B2	2/2011	Holtzman et al.
7,935,252	B2	5/2011	Mattner
7,935,348	B2	5/2011	Mattner et al.
8,591,894	B2	11/2013	Holtzman et al.
2002/0009445	A1	1/2002	Du et al.
2002/0037290	A1	3/2002	Armen
2004/0081657	A1	4/2004	Schenk
2006/0039906	A1	2/2006	Holtzman et al.
2009/0004210	A1	1/2009	Mattner et al.
2009/0104211	A1	4/2009	Mattner et al.
2009/0175853	A1	7/2009	Frangione et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	0236509	A1	9/1987
JP	6-104122	B2	12/1994

(Continued)

OTHER PUBLICATIONS

DeMattos et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. Jul. 17, 2001;98(15):8850-5. Epub Jul 3, 2001.*

Kojima. High-performance immunoaffinity chromatography, an immunoaffinity membrane for selective removal of plasma components, and safety evaluation of the latter system. J Biochem Biophys Methods. Oct. 30, 2001;49(1-3):241-51.*

Carro et al., Serum insulin-like growth factor I regulates brain amyloid-beta levels, Nat Med, vol. 8, pp. 1390-1397, 2002.

(Continued)

Primary Examiner — Gregory S Emch

(74) *Attorney, Agent, or Firm* — Troutman Sanders LLP

(57) **ABSTRACT**

Disclosed herein are methods for treating amyloid disease in humans by clearing amyloid peptides from one or more bodily fluids such as, e.g., blood, of a patient. In particular, the methods are based on the administration of compounds capable of binding to amyloid-beta (Aβ) or on dialysis of blood or plasma exchange in order to remove Aβ peptides from the blood circulation, and/or brain or other affected organs.

3 Claims, 4 Drawing Sheets